Nav: Home

Malaria hijacks your genes to invade your liver

June 27, 2019

DURHAM, N.C. -- In the search for new weapons against malaria, most drug development has focused on the parasites that cause the disease. But Duke University researchers are trying a different tack. Instead of targeting the malaria parasite directly, the idea is to discover drugs aimed at the human cell machinery conscripted to do malaria's dirty work.

In a new study, a team led by assistant professor of chemistry Emily Derbyshire has identified more than 100 human genes that malaria parasites commandeer to take up residence inside their victim's liver during the 'silent' earlier stages of infection, before symptoms appear.

Before their work only a few such genes were known. The findings could eventually lead to new ways to stop malaria parasites before people get sick and help keep the disease from spreading, via treatments that are less likely to promote resistance than existing malaria drugs, the researchers say.

The study appears online June 27 in the journal Cell Chemical Biology.

Malaria is caused by Plasmodium, a single-celled parasite spread through the bites of infected mosquitoes. Within hours of entering a person's body, the parasite finagles its way into a liver cell, which it uses as a sort of living nursery. There, it steals bits of the host's cell membrane to help build a protective pouch inside the cell where it quietly matures and multiplies before bursting out by the thousands into the bloodstream.

That's when the parasite starts to invade red blood cells and cause malaria's characteristic waves of fever and chills. The blood stage is also when parasites can be picked up by another biting mosquito and transmitted to the next person. If we could stop the parasite while it still lurks in the liver, before it reaches the blood, researchers say, we could keep people from developing symptoms or contributing to its spread.

For this study, researchers used snippets of silencing RNA to trick human liver cells into tamping down each of roughly 7,000 protein-coding genes. Then they infected the liver cells with a mouse malaria parasite similar to the Plasmodium species that causes human malaria. The researchers looked to see if, by preventing the cells from making a given protein, they could reduce the parasite load within the liver without killing the liver cells themselves.

The researchers identified over 100 human genes that malaria co-opts for its own benefit as it develops inside the liver, including several involved in carrying cargo between different cell compartments that the team is investigating further. Drugs that suppress some of these targets could potentially stunt the parasite's development before it runs rampant in the blood, the researchers say.

Drugs to prevent and treat malaria have been around for centuries. And yet worldwide the disease still kills about 500,000 people a year, in part because parasite populations have developed ways to evade attack.

"Many of the drugs that are available aren't working very well because of resistance," Derbyshire said.

Some say the only way to stay ahead is to keep finding new drugs. The early liver stage is seen as a promising target because people harbor fewer parasites at that point, which could slow the rise of resistance.

"Even though tens of thousands of parasites come out of the liver, that's still a very small number compared to the billions that build up later in the blood stage," said co-first author Maria Toro-Moreno, a chemistry graduate student at Duke.

This choke point could make for an easier target, Toro-Moreno explained. "It's a population bottleneck. The parasite is vulnerable at this stage."

Lower numbers also mean the parasites in an infected person's body are less genetically diverse. A drug administered at this stage is less likely to promote resistance than one administered after Plasmodium has multiplied more, during which time random genetic mutations could arise that enable some parasite strains to survive treatment.

Identifying potential targets is just a first step in drug development, a process that can take over a decade and require millions of dollars of investment before reaching the clinic. But by better understanding the intimate relationship between the malaria parasite and its host, the researchers hope to get closer.
This research was supported by the National Institutes of Health (DP2AI138239, F32AI118294) and the Duke Translational Research Institute Pilot Program.

CITATION: "Discovery of Druggable Host Factors Critical to Plasmodium Liver-Stage Infection," Rene Raphemot, Maria Toro-Moreno, Kuan-Yi Lu, Dora Posfai and Emily R. Derbyshire. Cell Chemical Biology, June 27, 2019. DOI: 10.1016/j.chembiol.2019.05.011

Duke University

Related Malaria Articles:

Could there be a 'social vaccine' for malaria?
Malaria is a global killer and a world health concern.
Transgenic plants against malaria
Scientists have discovered a gene that allows to double the production of artemisinin in the Artemisia annua plant.
Fighting malaria through metabolism
EPFL scientists have fully modeled the metabolism of the deadliest malaria parasite.
Should we commit to eradicate malaria worldwide?
Should we commit to eradicate malaria worldwide, asks a debate article published by The BMJ today?
Investigational malaria vaccine shows considerable protection in adults in malaria season
An investigational malaria vaccine given intravenously was well-tolerated and protected a significant proportion of healthy adults against infection with Plasmodium falciparum malaria -- the deadliest form of the disease -- for the duration of the malaria season, according to new findings published in the Feb.
Why malaria mosquitoes like people with malaria
Malaria mosquitoes prefer to feed -- and feed more -- on blood from people infected with malaria.
Malaria superbugs threaten global malaria control
A lineage of multidrug resistant P. falciparum malaria superbugs has widely spread and is now established in parts of Thailand, Laos and Cambodia, causing high treatment failure rates for the main falciparum malaria medicines, artemisinin combination therapies (ACTs), according to a study published today in The Lancet Infectious Diseases.
Considering cattle could help eliminate malaria in India
The goal of eliminating malaria in countries like India could be more achievable if mosquito-control efforts take into account the relationship between mosquitoes and cattle, according to an international team of researchers.
Seasonal malaria chemoprevention in Senegalese children lowers overall malaria burden
Giving preventive antimalarial drugs to children up to age 10 during active malaria season reduced the cases of malaria in that age group and lowered the malaria incidence in adults, according to a randomized trial carried out in Senegal and published in PLOS Medicine by researchers from the Université Cheikh Anta Diop, Senegal, the London School of Hygiene & Tropical Medicine, UK, and other collaborators.
How malaria fools our immune system
OIST researchers reconstruct the 3-D structure of a malaria protein in combination with human antibodies.

Related Malaria Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Do animals grieve? Do they have language or consciousness? For a long time, scientists resisted the urge to look for human qualities in animals. This hour, TED speakers explore how that is changing. Guests include biological anthropologist Barbara King, dolphin researcher Denise Herzing, primatologist Frans de Waal, and ecologist Carl Safina.
Now Playing: Science for the People

#SB2 2019 Science Birthday Minisode: Mary Golda Ross
Our second annual Science Birthday is here, and this year we celebrate the wonderful Mary Golda Ross, born 9 August 1908. She died in 2008 at age 99, but left a lasting mark on the science of rocketry and space exploration as an early woman in engineering, and one of the first Native Americans in engineering. Join Rachelle and Bethany for this very special birthday minisode celebrating Mary and her achievements. Thanks to our Patreons who make this show possible! Read more about Mary G. Ross: Interview with Mary Ross on Lash Publications International, by Laurel Sheppard Meet Mary Golda...